Publications en collaboration avec des chercheurs de Hospital Universitario San Cecilio (31)

2024

  1. Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)

    Actas Dermo-Sifiliograficas

  2. [Translated article] Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

2023

  1. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain

    International Journal of Dermatology, Vol. 62, Núm. 5, pp. 700-706

  2. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus

    Acta Dermato-Venereologica, Vol. 103

  3. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

  4. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  5. Upadacitinib for moderate to severe atopic dermatitis

    Immunotherapy, Vol. 15, Núm. 11, pp. 799-808

  6. Updated Review on Treatment of Atopic Dermatitis

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 158-167

2022

  1. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

    Life

  2. Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study

    F1000Research, Vol. 11

  3. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

    Dermatologic Therapy, Vol. 35, Núm. 10

  4. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab

    Dermatologic Therapy, Vol. 35, Núm. 11

  5. Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review

    Life, Vol. 12, Núm. 8

  6. Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis

    Life, Vol. 12, Núm. 12

  7. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series

    International Journal of Dermatology, Vol. 61, Núm. 8, pp. 1029-1033

  8. Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

    LIFE-BASEL, Vol. 12, Núm. 9

  9. Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning

    International journal of environmental research and public health, Vol. 19, Núm. 17

2021

  1. 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain

    Anais Brasileiros de Dermatologia, Vol. 96, Núm. 6, pp. 787-790

  2. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice

    Dermatologic Therapy, Vol. 34, Núm. 2

  3. Risankizumab: A pilot study of short-term effectiveness and safety in real clinical practice

    Dermatologic Therapy